| Abedi, Mehrdad |
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation |
|
|
| Terminated | 3 | 130 | US | AB-205, E-CEL cells, Placebo | Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM) | Hodgkin Lymphoma, Non Hodgkin Lymphoma | 12/23 | 01/24 | | |
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001) |
|
|
| Recruiting | 2 | 25 | US | Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a | David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network | Sickle Cell Disease | 05/26 | 05/26 | | |
| Recruiting | 2 | 190 | Europe, US | Tabelecleucel, tab-cel®, ATA129, EBV-CTLs | Atara Biotherapeutics | Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma | 06/27 | 05/29 | | |
|
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) |
|
|
| Active, not recruiting | 1/2 | 153 | Europe, US | AUTO1, Obecabtagene autoleucel (obe-cel) | Autolus Limited | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 05/25 | 05/25 | | |
| Recruiting | 1 | 24 | US | CK0804 | Cellenkos, Inc. | Myelofibrosis | 04/24 | 04/24 | | |
OGFT001-001, NCT03802695: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies |
|
|
| Recruiting | 1 | 186 | US | OrcaGraft (Orca-Q) | Orca Biosystems, Inc. | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia | 04/26 | 04/28 | | |
| Not yet recruiting | 1 | 40 | US | NXC-201 CAR-T, HBI0101 CAR-T | Nexcella Inc. | Light Chain (AL) Amyloidosis | 12/26 | 01/39 | | |
NCT04422912: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) |
|
|
| Recruiting | 1 | 55 | US | DSG3-CAART or CABA-201 | Cabaletta Bio | Pemphigus Vulgaris | 01/29 | 01/29 | | |
| Mantzaris, Ioannis |
| Recruiting | 2 | 95 | Europe, US | Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza | Syros Pharmaceuticals | Acute Myeloid Leukemia | 04/28 | 04/28 | | |
NCT05682170: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 1/2 | 95 | US | ZN-d5 ZN-c3, Study Drug, ZN-c3 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | Acute Myeloid Leukemia (AML) | 03/25 | 02/26 | | |
|
NCT05342584: Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS |
|
|
| Recruiting | 1b | 99 | US | Venetoclax Oral Tablet, Daunorubicin, Cytarabine | Ioannis Mantzaris, AbbVie | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 12/28 | 12/28 | | |
| Lauer, Gunnar |
1-BETTER, NCT04825288: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 1/2 | 69 | US | XB2001 or Placebo | XBiotech, Inc. | Pancreatic Cancer | 02/24 | 05/24 | | |
| Recruiting | 1/2 | 200 | Europe, US | HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C) | Hookipa Biotech GmbH, Hookipa Biotech | HPV-Related Squamous Cell Carcinoma | 06/25 | 06/26 | | |
NCT05451849: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer |
|
|
| Active, not recruiting | 1/2 | 6 | US | TC-510, Fludarabine, Cyclophosphamide | TCR2 Therapeutics | Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer | 10/28 | 10/28 | | |
NCT04999384: First in Human, Dose Escalation Study of AN4005 |
|
|
| Recruiting | 1 | 31 | US, RoW | AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect | Adlai Nortye Biopharma Co., Ltd. | Advanced Solid Tumor, Advanced Lymphoma | 08/24 | 12/24 | | |
| Recruiting | 1 | 52 | US | CUE-102 | Cue Biopharma | Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer | 12/24 | 12/26 | | |
NCT05958199: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 |
|
|
| Recruiting | 1 | 131 | US | NPX267 | NextPoint Therapeutics, Inc. | Metastatic Malignant Neoplasm | 01/26 | 01/26 | | |
